title: Androgen receptor in male breast cancer.
abstract: We present the androgen receptor (AR) status in 32 breast cancers diagnosed in male patients. Androgen receptor expression was found in 62.5% tumors and it was more frequent (85% of cases) in estrogen-positive tumours. The analyses of its impact on treatment results showed that AR immmunopositivity is a prognostic factor for overall survival, and AR immunonegativity is also correlated with worse prognosis (distant metastases developed more frequently and earlier).
authors.affiliation: Beata Sas-Korczynska MD, PhD, Oncology Clinic - Department of Breast and Chest Cancer, Maria Skłodowska-Curie Memorial Cancer Center, and Institute of Oncology, Krakow Branch, Garncarska 11, 31-115 Krakow, Poland, tel. +48 12 634 83 63, fax: +48 12 423 10 76, e-mail: z5korczy@cyf-kr.edu.pl.
authors.forename: Beata
authors.initials: B
authors.lastname: Sas-Korczynska
authors.forename: Aagnieszka
authors.initials: A
authors.lastname: Adamczyk
authors.forename: Joanna
authors.initials: J
authors.lastname: Niemiec
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Harazin-Lechowska
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Ambicka
authors.forename: Jerzy
authors.initials: J
authors.lastname: Jakubowicz
mesh_terms: D000368:Aged; D001940:Breast / Q000473:pathology; D018567:Breast Neoplasms, Male / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011944:Receptors, Androgen / Q000378:metabolism*; D012189:Retrospective Studies
chemical_list: D011944:Receptors, Androgen